Profile: Conatus Pharmaceuticals Inc (CNAT.OQ)
26 Jun 2019
Conatus Pharmaceuticals Inc., incorporated on July 13, 2005, is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease.
Emricasan is an orally active caspase protease inhibitor designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation. Caspase activation and regulation is tightly controlled through a number of mechanisms. All caspases are expressed as enzymatically inactive forms known as pro-caspases, which can be activated following a range of cellular insults or stimuli. Caspase mediated apoptosis is driven primarily by the activity of caspases 3 and 7, which by virtue of their enzymatic activity, cleave a range of cellular proteins and result in dismantling of the cell. Other apoptotic caspase family members are principally involved in sensing and transmitting signals from either outside or inside the cell. These signals converge to activate pro-caspases three and seven, enabling them to carry out the process of apoptosis.
The Company's cirrhosis trials enrolled and treated patients whose cirrhosis was due to a variety of etiologies, including hepatitis C virus (HCV), infection, alcohol or nonalcoholic steatohepatitis (NASH). The Company's focuses on conducting a set of parallel EmricasaN, a Caspase inhibitOR, for Evaluation clinical trials, or the ENCORE trials, designed to provide further information on doses leading to clinically relevant efficacy, including improvement in biopsy-proven fibrosis and inflammation in patients with NASH fibrosis, and improvement in severe portal hypertension and hepatic function in patients with NASH cirrhosis.
Conatus Pharmaceuticals Inc
16745 W Bernardo Dr Ste 200
SAN DIEGO CA 92127-1906
Company Web Links
- UPDATE 1-Conatus Pharma to explore options as liver disease drug fails trial
- BRIEF-Conatus Says Top-Line Results From Encore-LF Clinical Trial Of Emricasan Did Not Meet Primary Endpoint
- Conatus Pharma to explore options, liver disease drug fails trial
- BRIEF-Conatus Completes Enrollment In Phase 2B Clinical Trial Of Emricasan In Patients With Decompensated Nash Cirrhosis